Hemophagocytic Lymphohistiocytosis Clinical Trial
Official title:
Cytokine Blockade With Tocilizumab in Patients With Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis
This study seeks to determine the efficacy of tocilizumab (TCZ) in patients with hemophagocytic lymphohistiocytosis (HLH) and high cytokine levels (proteins involved in inflammation) in an attempt to decrease the damage caused by these proteins; and secondarily to assess its safety and impact on disease activity.
Subjects with hemophagocytic lymphohistiocytosis (HLH) often have life-threatening complications at the time of diagnosis resulting from excessive inflammation. This excessive inflammation is driven by abnormally high levels of cytokines--proteins involved in inflammation. Standard therapy for HLH does not directly target these cytokines. Tocilizumab is a medicine that blocks one of the cytokines that is elevated in patients with HLH. This is an open-label single-arm uncontrolled trial with biologic endpoint. This study will use tocilizumab in subjects with HLH and high cytokine levels in an attempt to decrease the damage caused by these proteins. All subjects will receive standard therapy, in addition to tocilizumab. We hypothesize the tocilizumab will decrease levels of certain important cytokines. This may make it easier to treat subjects with HLH overall. TCZ will be administered as a single dose (8mg/kg) intravenously. Eligible subjects will be inpatients at the Children's Hospital of Philadelphia (CHOP) main campus. 10 subjects with HLH will be enrolled. All subjects will be initiated on standard HLH-directed treatment. Cytokine levels [including serum interferon (IFN-γ) and interleukin (IL-6)] will be monitored, in addition to other laboratory and clinical markers of HLH disease activity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
| Recruiting |
NCT02912702 -
L-DEP as an Initial Treatment for EBV-HLH
|
Phase 3 | |
| Terminated |
NCT00176826 -
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06038422 -
GTP Regimen in the Treatment of Refractory/Recurrent HLH
|
Phase 3 | |
| Completed |
NCT03510650 -
Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
|
||
| Completed |
NCT03259230 -
Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
|
||
| Active, not recruiting |
NCT01494103 -
Administration of Donor T Cells With the Caspase-9 Suicide Gene
|
Phase 1 | |
| Recruiting |
NCT05164978 -
DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH
|
N/A | |
| Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
| Terminated |
NCT01547143 -
Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
|
N/A | |
| Active, not recruiting |
NCT00006056 -
Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders
|
N/A | |
| Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
| Recruiting |
NCT03795909 -
Ruxolitinib Combined With Dexamethasone for HLH
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03533790 -
DEP-Ru Regimen as a Salvage Therapy for HLH
|
Phase 3 | |
| Not yet recruiting |
NCT05315336 -
L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
|
Phase 3 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Recruiting |
NCT04326348 -
A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）
|
Phase 1 | |
| Recruiting |
NCT04551131 -
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05546060 -
Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
|
Phase 1 | |
| Recruiting |
NCT05137522 -
Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
|
N/A |